RT Conference Proceedings
T1 Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+HR+ breast cancer after trastuzumab-based therapy on patient outcomes
A1 Martin Jimenez, M.
A1 Gnant, M. I.
A1 Ejlertsen, B.
A1 Mansi, J. L.
A1 Ruiz-Borrego, M.
A1 Jakobsen, E. H.
A1 Osborne, C. K.
A1 Birhiray, R.
A1 Zhang, B.
A1 Wong, A.
A1 Moy, B.
A1 Holmes, F. A.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-05-01
LK https://hdl.handle.net/10668/27209
UL https://hdl.handle.net/10668/27209
LA en
DS RISalud
RD Apr 6, 2025